Ryan Andrew Irvine, Age 559140 25Th St, Los Angeles, CA 90034
Ryan Irvine Phones & Addresses
9140 25Th St, Los Angeles, CA 90034 (310) 815-0563 (310) 815-9463
1732 Berkeley Sq, Berkeley, CA 94703 (510) 549-3665 (510) 549-3880
Gloucester City, NJ
Manhattan Beach, CA
Issaquah, WA
Chestnut Hill, MA
9140 W 25Th St, Los Angeles, CA 90034
Work
Position:
Professional/Technical
Education
Degree:
Associate degree or higher
Mentions for Ryan Andrew Irvine
Publications & IP owners
Us Patents
Methods For Enhancing Therapeutic Effects Of A Neurotoxin
US Patent:
2007016, Jul 12, 2007
Filed:
Jan 12, 2006
Appl. No.:
11/330893
Inventors:
Eric First - Boston MA, US
Ryan Irvine - Los Angeles CA, US
Ryan Irvine - Los Angeles CA, US
Assignee:
ALLERGAN, INC. - Irvine CA
International Classification:
A61K 39/08
US Classification:
424239100
Abstract:
The present invention relates to methods for enhancing the therapeutic effects of a neurotoxin, e.g., a toxin, where the methods comprise a “wash-down” (e.g., a decreased intake) of a current pain medication and an administration of a neurotoxin. In some embodiments, the present inventions relates to methods for enhancing the therapeutic effects of a neurotoxin for treating pain, e.g., headache pain.
Methods For Enhancing Skin Treatments
US Patent:
2007017, Aug 2, 2007
Filed:
Dec 5, 2006
Appl. No.:
11/566859
Inventors:
Eric R. First - Boston MA, US
Ryan S. Irvine - Los Angeles CA, US
Ryan S. Irvine - Los Angeles CA, US
Assignee:
ALLERGAN, INC. - Irvine CA
International Classification:
A61K 39/08
A61K 8/73
A61K 8/64
A61K 31/728
A61K 8/73
A61K 8/64
A61K 31/728
US Classification:
4242391, 514 54, 424 7013, 424 7014
Abstract:
The present invention relates to methods for enhancing the result of a skin treatment for a human patient. In some embodiments, the methods comprise the step of administering a neurotoxin to a skin area designated for the skin treatment. The skin treatment includes the application of a dermatologic agent and/or procedure.
Early Treatment And Prevention Of Increased Muscle Tonicity
US Patent:
2010012, May 20, 2010
Filed:
Oct 13, 2009
Appl. No.:
12/578518
Inventors:
Andrew M. BLUMENFELD - Del Mar CA, US
Ryan A. IRVINE - Los Angeles CA, US
Ryan A. IRVINE - Los Angeles CA, US
Assignee:
ALLERGAN, INC. - Irvine CA
International Classification:
A61K 39/08
US Classification:
4242391
Abstract:
Described herein are methods of preventing, modulating and treating spasticity and maladaptive neuronal plasticity in patients having upper motor neuron lesions or have had a traumatic central nervous system event by early intervention methods. The methods comprise the step of administering a therapeutically effective amount of a botulinum toxin or derivative thereof to least a portion of a 1A sensory afferent of at least one muscle prior to development of spasticity or maladaptive neuronal plasticity becomes clinically apparent. The therapeutically effective amount of botulinum toxin administered to the 1A afferent of the muscle does not substantially affect the Golgi tendons therein.
Determining General Causation
US Patent:
2021027, Sep 2, 2021
Filed:
Nov 25, 2020
Appl. No.:
17/247060
Inventors:
- Los Angeles CA, US
Lauren Caston - Los Angeles CA, US
Ryan Irvine - Los Angeles CA, US
David Loughran - Los Angeles CA, US
Robert Thomas Reville - Los Angeles CA, US
Lauren Caston - Los Angeles CA, US
Ryan Irvine - Los Angeles CA, US
David Loughran - Los Angeles CA, US
Robert Thomas Reville - Los Angeles CA, US
International Classification:
G06N 5/04
G06F 16/93
G06F 17/11
G06N 7/00
G06F 16/93
G06F 17/11
G06N 7/00
Abstract:
Examples of the disclosure are directed toward generating a causation score with respect to an agent and an outcome, and projecting a future causation score distribution. For example, a causation score may be determined with respect to a hypothesis that a given agent causes a given outcome, and the score may indicate the acceptance of that hypothesis in the scientific community, as described by scientific literature. A future causation score distribution, then, may indicate a probability distribution over possible future causation scores, thereby predicting the scientific acceptance of the hypothesis at some specific date in the future. A future causation score distribution can be projected by first generating one or more future publication datasets, and then determining causation scores for each of the one or more future publication datasets.
Determining General Causation
US Patent:
2016032, Nov 10, 2016
Filed:
Jul 22, 2016
Appl. No.:
15/217820
Inventors:
- Los Angeles CA, US
Lauren CASTON - Los Angeles CA, US
Ryan IRVINE - Los Angeles CA, US
David LOUGHRAN - Los Angeles CA, US
Robert Thomas REVILLE - Los Angeles CA, US
Lauren CASTON - Los Angeles CA, US
Ryan IRVINE - Los Angeles CA, US
David LOUGHRAN - Los Angeles CA, US
Robert Thomas REVILLE - Los Angeles CA, US
International Classification:
G06N 5/04
G06N 7/00
G06F 17/11
G06F 17/30
G06N 7/00
G06F 17/11
G06F 17/30
Abstract:
Examples of the disclosure are directed toward generating a causation score with respect to an agent and an outcome, and projecting a future causation score distribution. For example, a causation score may be determined with respect to a hypothesis that a given agent causes a given outcome, and the score may indicate the acceptance of that hypothesis in the scientific community, as described by scientific literature. A future causation score distribution, then, may indicate a probability distribution over possible future causation scores, thereby predicting the scientific acceptance of the hypothesis at some specific date in the future. A future causation score distribution can be projected by first generating one or more future publication datasets, and then determining causation scores for each of the one or more future publication datasets.
Determining General Causation
US Patent:
2015017, Jun 25, 2015
Filed:
Dec 19, 2013
Appl. No.:
14/135436
Inventors:
- Culver City CA, US
Lauren CASTON - Culver City CA, US
Ryan IRVINE - Culver City CA, US
David LOUGHRAN - Culver City CA, US
Robert Thomas REVILLE - Culver City CA, US
Lauren CASTON - Culver City CA, US
Ryan IRVINE - Culver City CA, US
David LOUGHRAN - Culver City CA, US
Robert Thomas REVILLE - Culver City CA, US
Assignee:
PRAEDICAT, INC. - Culver City CA
International Classification:
G06N 5/04
Abstract:
Examples of the disclosure are directed toward generating a causation score with respect to an agent and an outcome, and projecting a future causation score distribution. For example, a causation score may be determined with respect to a hypothesis that a given agent causes a given outcome, and the score may indicate the acceptance of that hypothesis in the scientific community, as described by scientific literature. A future causation score distribution, then, may indicate a probability distribution over possible future causation scores, thereby predicting the scientific acceptance of the hypothesis at some specific date in the future. A future causation score distribution can be projected by first generating one or more future publication datasets, and then determining causation scores for each of the one or more future publication datasets.
NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.